StreetInsider.com News Articles

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

Thu, 22 Oct 2026 08:00:00 -0400

PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/54689.

For those unable to listen to the live

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

Thu, 22 Oct 2026 08:00:00 -0400

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/54689.

For those unable to listen to the live

Krystal Biotech (KRYS) PT Raised to $416 at Citi

Thu, 15 Oct 2026 13:09:49 -0400

Citi analyst Yigal Nochomovitz raised the price target on Krystal Biotech (NASDAQ: KRYS) to $416.00 (from $386.00) while maintaining a Buy rating.

Form 8-K Krystal Biotech, Inc. For: Oct 15

Thu, 15 Oct 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20261015/27189509.html

Krystal Biotech reports KB113 lesion regression data in Gorlin syndrome

Thu, 15 Oct 2026 07:01:36 -0400

Krystal Biotech, Inc. (NASDAQ: KRYS) released clinical data from a pilot study of KB113, an investigational intratumoral immunotherapy, showing that over 80% of assessed basal cell carcinoma (BCC) lesions regressed across three patients with Gorlin syndrome.

According to the company's press release, 69 of 83 assessed landmark lesions showed any clinical regression at the final assessment, conducted 30 days after the last dose. Of those, 42 of 83 lesions demonstrated greater than 50% regression, and 8 of 83 showed at least 90% regression. One injected lesion per patient that reached at least 90% clinical regression was biopsied, and all three showed

Krystal Biotech reports KB113 lesion regression data in Gorlin syndrome

Thu, 15 Oct 2026 07:01:36 -0400

Krystal Biotech reports KB113 lesion regression data in Gorlin syndrome

Thu, 15 Oct 2026 07:01:36 -0400

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Thu, 15 Oct 2026 07:00:00 -0400

Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113

Substantial regression was observed in lesions not directly injected with KB113, consistent with abscopal effect

KB113 injections were well tolerated by Gorlin syndrome patients; all reported adverse events were mild to moderate in severity and transient in nature

Data will be presented by study investigator Dr. Shireen Guide at the 14th PeDRA Annual Conference, October 15-17, 2026

PITTSBURGH, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Thu, 15 Oct 2026 07:00:00 -0400

Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113

Substantial regression was observed in lesions not directly injected with KB113, consistent with abscopal effect

KB113 injections were well tolerated by Gorlin syndrome patients; all reported adverse events were mild to moderate in severity and transient in nature

Data will be presented by study investigator Dr. Shireen Guide at the 14th PeDRA Annual Conference, October 15-17, 2026

PITTSBURGH, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the

Goldman Sachs Assumes Krystal Biotech (KRYS) at Buy

Thu, 24 Sep 2026 05:36:06 -0400

(Updated - September 24, 2026 5:36 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Krystal Biotech (NASDAQ: KRYS) with a Buy rating and a price target of $441.00.

The analyst comments "KRYS is a profitable, commercial-stage, global biotechnology company leveraging its redosable HSV-1-based gene therapy platform for the treatment of rare diseases. Its lead commercial drug Vyjuvek (topical gel) is the first approved treatment for dystrophic epidermolysis bullosa (DEB; genetic skin condition characterized by blisters, wounds, and scars), where it has achieved 60%+ penetration in US markets and is actively scaling an exUS rollout. KRYS also boasts an extensive clinical

Goldman Sachs Assumes Krystal Biotech (KRYS) at Buy

Thu, 24 Sep 2026 05:36:06 -0400

(Updated - September 24, 2026 5:36 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Krystal Biotech (NASDAQ: KRYS) with a Buy rating and a price target of $441.00.

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: ROSSI DINO A

Wed, 16 Sep 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260916/27071539.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: Sutherland Everett Rand

Wed, 16 Sep 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260916/27071536.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: Mazzacco Catherine

Wed, 16 Sep 2026 20:02:00 -0400

si-local-file:///var/storage/secattach/20260916/27071535.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: Mason Christopher

Wed, 16 Sep 2026 20:02:00 -0400

si-local-file:///var/storage/secattach/20260916/27071532.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: JANNEY DANIEL

Wed, 16 Sep 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260916/27071531.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: Gangolli Julian S

Wed, 16 Sep 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260916/27071528.html

Form 4 Krystal Biotech, Inc. For: Aug 14 Filed by: ROSSI DINO A

Fri, 14 Aug 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26933125.html

Form 4 Krystal Biotech, Inc. For: Aug 14 Filed by: ROSSI DINO A

Fri, 14 Aug 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26933125.html

Form 144 Krystal Biotech, Inc. Filed by: ROSSI DINO A

Fri, 14 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26932828.html

Form 144 Krystal Biotech, Inc. Filed by: ROSSI DINO A

Fri, 14 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26932828.html

RBC Capital Starts Krystal Biotech (KRYS) at Outperform

Fri, 14 Aug 2026 05:28:07 -0400

RBC Capital initiates coverage on Krystal Biotech (NASDAQ: KRYS) with a Outperform rating and a price target of $400.00.

For an analyst ratings summary and ratings history on Krystal Biotech click here. For more ratings news on Krystal Biotech click here.

Shares of Krystal Biotech closed at $328.34 yesterday.

Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

Tue, 11 Aug 2026 15:35:51 -0400

News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.

RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and

Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

Tue, 11 Aug 2026 15:35:51 -0400

News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.

Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

Tue, 11 Aug 2026 15:35:51 -0400

News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.